- Home
- HCKT vs MNPR Comparison
HCKT vs MNPR Comparison
Compare HCKT & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HCKT | MNPR |
|---|---|---|
| Founded | 1991 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 500.5M | 531.6M |
| IPO Year | 1998 | 2019 |
Fundamental Metrics
Financial Performance| Metric | HCKT | MNPR |
|---|---|---|
| Price | $19.93 | $65.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 13 |
| Target Price | $27.00 | ★ $97.83 |
| AVG Volume (30 Days) | ★ 325.1K | 297.9K |
| Earning Date | 02-17-2026 | 11-13-2025 |
| Dividend Yield | ★ 2.40% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | ★ $303,482,000.00 | N/A |
| Revenue This Year | $0.07 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $52.13 | ★ N/A |
| Revenue Growth | ★ 0.91 | N/A |
| 52 Week Low | $17.53 | $22.50 |
| 52 Week High | $34.02 | $105.00 |
Technical Indicators
Market Signals| Indicator | HCKT | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 56.41 | 39.01 |
| Support Level | $19.41 | $56.15 |
| Resistance Level | $20.16 | $70.01 |
| Average True Range (ATR) | 0.36 | 4.70 |
| MACD | -0.05 | -0.39 |
| Stochastic Oscillator | 42.75 | 47.00 |
Price Performance
Historical ComparisonAbout HCKT Hackett Group Inc (The).
The Hackett Group Inc is an IP platform-based Generative Artificial Intelligence (Gen AI) strategic consulting and executive advisory digital transformation firm. The Hackett Group provides dedicated expertise in Gen AI-enabled enterprise transformation services across the front, mid and back office areas, including its highly recognized Oracle, SAP, OneStream and Coupa implementation offerings. It operates in three segments Oracle Solutions, SAP Solutions, and Global S&BT. It generates the majority of its revenue from the Global S&BT segment in the United States.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.